MAIA Biotechnology reports patient enrollment milestones in Phase 2 and Phase 3 NSCLC trials
MAIA Biotechnology said it achieved patient enrollment milestones in its ongoing Phase 2 and pivotal Phase 3 clinical trials in non-small cell lung cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.